Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Sarcoma 3Plasma cell 3Other hematologic neoplasm 3Breast 3Gastrointestinal 2Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Gastrointestinal Stromal Tumors 2Sarcoma 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × tanespimycin × Gastrointestinal × Clear all
NCT00688766 2012-12-11

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Infinity Pharmaceuticals, Inc.

Phase 3 Terminated
47 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00276302 2011-01-06

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Infinity Pharmaceuticals, Inc.

Phase 1 Completed
63 enrolled
GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡